drugset / Trial / NCT03424239

Pilot Study for Zoledronic Acid to Prevent Bone Loss After Bariatric Surgery

NCT03424239

Phase 4 Completed 6 enrolled Massachusetts General Hospital
NaSingle-groupOpen-labelPrevention

Summary

This study evaluates whether zoledronic acid can prevent the high bone turnover that occurs after Roux-en-Y Gastric Bypass (RYGB) and sleeve gastrectomy (SG) surgery.

Timeline

Start
2018-08-01
Primary completion
2020-01-01
Completion
2020-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified 5 mg Intravenous

Indications

No indication recorded.